Content Type: Article

  • The FTC’s strategy on noncompetes: What employers should know in 2026

    The FTC’s strategy on noncompetes: What employers should know in 2026

    ARTICLE / CLIENT ALERT

    The FTC’s strategy on noncompetes: What employers should know in 2026

    April 21, 2026

    Read time: 8 min

    Key takeaways
    Overview

    Employers who assumed the demise of the Federal Trade Commission’s noncompete rule meant a regulatory reprieve may be surprised by the agency’s renewed focus on enforcement through individual investigations and consent orders.

    Noncompete agreements, which are contracts that limit employees’ employment after leaving a job, have been the subject of debate in recent years at the Federal Trade Commission (FTC). The FTC’s ambitious but short-lived attempt to ban most noncompetes nationwide in 2024 ended after the rule was blocked in court and ultimately abandoned by the FTC. Rather than pursuing a categorical prohibition, the agency is now relying on targeted, case-by-case enforcement actions against noncompete provisions it views as anticompetitive.

    FTC leadership has made clear it intends to prioritize enforcement of illegal noncompetes. Over the past several months, the FTC has reinforced its commitment through public statements, warning letters, consent orders, and a workshop on noncompetes. For employers, these developments signal that noncompetes remain very much on the FTC’s radar, even without a formal rule in place. This article reviews the recent history of the FTC’s noncompete efforts, summarizes the agency’s new enforcement posture, and offers practical guidance for minimizing risk in the current regulatory environment where employer noncompete practices are back in the spotlight.

    In depth

    Recent history of the FTC’s noncompete rule

    In April 2024, during then-Chair Lina Khan’s final year leading the agency, the FTC issued a final rule banning nearly all employer/employee noncompete clauses. The rule would have prohibited employers from restricting workers’ ability to move to competitors or start competing businesses, with only limited exceptions. The FTC estimated that the rule would affect approximately 18% of US workers, making it one of the most sweeping labor market regulations the agency ever issued.

    The rule passed along party lines on a narrow 3-2 vote. Commissioners Melissa Holyoak and Andrew Ferguson dissented, each issuing separate statements questioning both the FTC’s statutory authority and the economic justification for a categorical ban on noncompetes. Both emphasized that noncompetes generally should be evaluated under the rule of reason, meaning that any anticompetitive effects should be weighed against any procompetitive effects to form a holistic view of the overall effect of the agreement.

    Before the rule could take effect, it faced immediate legal challenges. Federal lawsuits filed in Texas and Florida argued that the FTC lacked authority under the Federal Trade Commission Act to issue substantive competition rules of this scope. On August 20, 2024, a federal district court in Texas issued an order preventing the FTC from enforcing the noncompete rule nationwide.

    The FTC appealed that decision on October 18, 2024, setting the stage for what could have been a lengthy appellate battle over the agency’s rulemaking authority.

    A change in leadership – and direction – at the FTC

    Following the election in 2025, the FTC’s leadership changed, and the commissioners who formed the majority in favor of the noncompete rule were no longer at the agency. The new leadership announced they would no longer pursue ongoing appeals to allow enforcement of the rule. The practical effect was to moot the rule entirely; it never went into effect and the agency is no longer defending it.

    The FTC’s new strategy: Individualized enforcement

    Rather than attempting another across-the-board rulemaking, Chair Ferguson has made clear that the FTC will instead pursue individualized enforcement actions against noncompetes that it views as anticompetitive. Without a bright-line rule, the agency has emphasized that enforcement will focus on specific facts and circumstances. In recent months, however, the FTC has signaled its commitment to regulate noncompetes through several initiatives:

    • Complaint intake: In 2024, the FTC established a dedicated email address (noncompete@ftc.gov) for workers and others to submit complaints regarding noncompete agreements, which the FTC continually monitors.
    • Joint Labor Task Force: Chair Ferguson announced the creation of a Joint Labor Task Force composed of staff from the Bureaus of Competition, Consumer Protection, Economics, and Policy Planning. The task force is intended to coordinate investigations and enforcement actions related to labor market competition, including noncompetes. The FTC recently highlighted this taskforce in its accomplishments for 2025, and stated that “[n]oncompete agreements remain a focus of enforcement.”
    • Healthcare industry warning letters: The FTC issued warning letters to certain companies in the healthcare industry, highlighting concerns about noncompetes and other restrictive agreements limiting employment options for important roles in healthcare and restricting patient choice. In particular, the letter emphasized that these restrictive employment practices could be harmful in rural areas where medical care is limited.
    • Workshop on noncompete agreements: The FTC hosted a workshop with speakers, including Chair Ferguson and Commissioner Meador discussing noncompete agreements. At the workshop, Chair Ferguson emphasized that employers should study these consent orders carefully to understand how the FTC is likely to evaluate noncompete practices going forward. The workshop also highlighted the healthcare industry, with all panelists in the session titled “Victims of Anticompetitive Noncompete Agreements” representing the broader healthcare field.
    • FTC 2026 – 2030 strategic plan: The FTC’s recently released 2026 – 2030 strategic plan includes researching and investigating the impacts of “no-poach, non-solicitation, no-hire agreements, noncompete agreements, and wage-fixing agreements” for workers.
    • Enforcement actions and consent orders: The FTC has initiated enforcement actions against several companies whose noncompete agreements the agency found particularly problematic, resulting in consent orders. With no formal rule in place, recent FTC consent orders provide the clearest insight into the agency’s enforcement priorities.

    Enforcement actions provide insight into enforcement priorities

    In the past six months, the FTC has brought three enforcement actions related to employee noncompetes, emphasizing the FTC’s continued scrutiny of noncompetes:

    In Gateway Services, the FTC challenged noncompete agreements that applied broadly across the company’s workforce. The restrictions covered everyone from highly compensated executives to hourly employees, affecting approximately 1,800 workers. The FTC took issue with the lack of individualized consideration of employees’ roles, including not considering access to confidential information or competitive risk posed by their departure which would have provided procompetitive reasoning for the restrictions.

    In Adamas Amenity Services, the FTC focused on a no-hire agreement involving low-wage workers. No-hire agreements are similar to noncompetes, but the agreement is between the employer and another company, rather than between the employee and the employer. The FTC alleges no-hire agreements similarly restrict employee job movement. In Adamas, the arrangement not only restricted competitors’ ability to hire workers but also, in some cases, prevented Adamas’ clients from switching vendors. The FTC viewed the agreement as suppressing worker mobility and competition without sufficient justification tied to legitimate business interests.

    In Rollins, the FTC brought a complaint alleging that the pest-control company’s noncompete agreement was anticompetitive. The noncompete agreement applied to more than 18,000 employees regardless of role, with the majority of covered employees being relatively low-wage earners. The FTC alleged employees were given no additional compensation for signing the agreement nor were they given the opportunity to understand what they were signing. In addition, the FTC alleged Rollins had a history of enforcing these agreements through cease-and-desist letters and lawsuits. Rollins entered into a settlement with the FTC, agreeing to stop enforcing the noncompetes. The FTC also stated it sent warning letters to other pest-control companies asking them to review their employee agreements for anticompetitive noncompetes.

    Keep in mind state enforcement

    In addition to increased federal enforcement, states have also heightened enforcement of noncompetes on a local level, including some states implementing bans on noncompetes. Four states currently have full bans on noncompetes, and Washington will become the fifth state when a recently passed bill takes effect in 2027. Other states have statutes addressing and limiting noncompetes; for instance, Illinois only permits noncompetes for individuals who earn above a certain threshold and imposes certain procedural requirements. Further, each state has developed their own body of case law outlining the bounds of acceptable restrictions. Any noncompete agreement should be reviewed for compliance with applicable state law.

    Key takeaways emerging from FTC enforcement of noncompetes

    Notably, the FTC’s abandonment of its nationwide noncompete rule does not signal a retreat from labor market enforcement. Instead, the agency has pivoted to a more targeted strategy, relying on individualized investigations and consent orders to shape employer behavior. For companies that utilize restrictive covenants with employees, employers should undertake a particularized analysis, use careful drafting, and regularly review such agreements in light of ongoing FTC enforcement. Below are takeaways employers can glean from recent enforcement actions:

    • Blanket noncompetes are high risk: Company-wide noncompetes that apply uniformly to all employees regardless of role, compensation, or access to sensitive information are particularly vulnerable to challenge. In particular, noncompetes affecting lower-wage or lower-skill workers are more likely to be viewed as anticompetitive, especially where such workers are unlikely to possess trade secrets or strategic information.
    • Healthcare is a special focus: In healthcare, the FTC has emphasized concerns about patient choice and access to care. Noncompetes that could limit access to healthcare services, particularly in rural or underserved areas, may attract stricter scrutiny from the FTC.
    • Unreasonable limits to competition are also considered: A noncompete that not only affects labor rights but also affects competition between companies is more likely to be scrutinized. These agreements are reviewed holistically. Where multiple types of anticompetitive harm are present, then the procompetitive benefits may be harder to offset. Before including restrictions on labor, carefully consider whether those provisions have legitimate business justifications.
    Authors

    Lisa P. Rumin

    Partner

    Washington, DC

    Chelsea Mounayer

    Counsel

    Chicago

    Barrick Bollman

    Partner

    Chicago

    Brian Mead

    Partner

    Chicago

    More insights

  • California at a crossroads: SB 254 study maps systemic reforms for wildfire and catastrophe resilience

    California at a crossroads: SB 254 study maps systemic reforms for wildfire and catastrophe resilience

    ARTICLE / CLIENT ALERT

    California at a crossroads: SB 254 study maps systemic reforms for wildfire and catastrophe resilience

    April 21, 2026

    Read time: 7 min

    Key takeaways
    Overview

    In 2025, the California legislature tasked the California Earthquake Authority (CEA), as administrator of the state’s Wildfire Fund, to prepare the Senate Bill 254 (2025) Study Report, considering 10 recommendations that the state legislature and Governor Newsom agreed should be studied to help California become more resilient to natural catastrophes:

    1. Enhance access to and affordability of property insurance
    2. Evaluate options to socialize the financial risk of natural catastrophes
    3. Consider mitigation measures and technology solutions to reduce the incidence of wildfires and retard their spread
    4. Develop ways to speed compensation to victims of wildfires and speed recovery
    5. Protect utility ratepayers by helping utilities improve safety and reduce wildfire risk
    6. Streamline and lower the costs of compensating those injured by wildfires
    7. Consider ways and means to limit the cost of claims for wildfire damage, including possible damage limitations (e.g., establishing per-event aggregate limits, limiting public entity damage awards, capping attorneys’ fees, and limiting the ability of property owners outside wildfire perimeters to recover damages)
    8. Related to number 3 above, lower the risk of wildfires spreading by implementing property-specific and community-wide hardening and similar measures
    9. Close insurance gaps with minimum insurance requirements, match insurance rate reductions/discounts with mitigation measures, and improve emergency responses and land use planning
    10. Consider new models and structures to replace or complement the state’s Wildfire Fund

    The authors make the case for an “all-of-government, all-of-society” effort to solve interconnected problems and achieve the following goals:

    • Supplying Californian ratepayers with affordable, reliable, clean, and safe electric energy
    • Providing California property owners with affordable, competitive, fairly regulated property insurance
    • Ensuring safe and resilient communities

    The report acknowledges that climate change is “systematically” pressuring – and will continue to pressure – efforts to achieve these goals.

    In depth

    Resilience under pressure: The case for immediate action

    The report begins by summarizing current conditions and challenges, as well as California’s recent response to its history of devastating wildfires, culminating with the creation of the Wildfire Fund, which focuses on wildfires attributable to electric utilities. The report is frank in acknowledging that the status quo is not working – utilities are “unstable and at risk,” while the willingness of insurers to cover property in wildfire-prone locations (which now includes much of the state) is “limited and fragile.”

    The report includes an in-depth review of the current state of California’s electric utility sector, stressing the critical importance to the state’s economy and environment – and to ratepayers – of utilities’ access to credit markets. It is in no one’s interest to have financially distressed utilities, whether publicly or privately owned, supplying electric power to Californians. The report highlights the considerable risk-mitigation improvements made by electric utilities in recent years but also notes the limits of those efforts. Utilities can do little to reverse decades of development in the wildland urban interface (WUI), the buildup of wildfire fuels in those areas, and the uneven, limited property-specific and community-wide hardening and risk reduction.

    The report also describes the current state of the insurance sector as the “financial first responder” to wildfires. A large percentage of California homeowners are underinsured. Some have no wildfire coverage, but this “insurance gap” is not as pronounced as gaps for flood and earthquake coverage. Take-up rates for coverage against the latter two perils are quite low. Accordingly, the report concludes that solving for all three perils at this time is likely not financially feasible.

    The report notes the recent increase in properties insured by the California FAIR Plan, particularly in wildfire-prone regions, amounting to roughly 10% of the state’s residential structures. The FAIR Plan is now the only (or the primary) available insurance market in the most exposed locations, rather than functioning as a last resort as originally designed. But when the plan exhausts its assets, California’s state-licensed insurers – all of which participate in the plan – bear allocated shares of liability. When FAIR Plan losses increase, insurers can surcharge policies. They can also subrogate against utilities when losses are attributable to utility equipment or operations. Utilities can then claim against the Wildfire Fund as losses increase – hence, the interconnectedness of “the system” for compensating wildfire losses.

    An interconnected system under compounding strain

    Putting together the state’s property insurance market conditions with the current electric utility financial system and the existing “fragmented and undersized” wildfire risk mitigation picture, the report asserts that the time for incremental adjustments has passed. As the report addresses at some length, inaction has both “large near-term and severe long-term adverse consequences” for California’s communities, insurers, electric utilities, and electric power ratepayers.

    Pathways to resilience: Strategies and options

    The Report uses “no action” as a baseline against which to measure three policy pathways:

    • Reducing community risk
    • Equitably allocating the costs of catastrophes
    • Improving resiliency

    Within each pathway, the report examines cost-benefit tradeoffs and presents strategies and options. The authors acknowledge considerable timing differences across the pathways in terms of execution, but the aim of the report is to set out “actionable, viable, and durable” steps for the California legislature and the governor to consider to help the state increase resiliency.

    Key takeaways: Policy tradeoffs and near-term decisions

    The first pathway includes a variety of community-wide, coordinated strategies and options to incentivize and facilitate reductions in wildfire risk, producing beneficial results but not in the near term (i.e., the next one to two years). Rather, the report acknowledges that results from this pathway can be expected over years and decades.

    The second pathway proposes options with shorter execution timelines, including enacting legislation to reform the FAIR Plan (restoring it to its original purpose as a last-resort property insurer, changing legal liability standards for utilities, and establishing a more durable Wildfire Fund. The option limiting damages recoverable by property owners outside wildfire perimeters is one example of the tradeoffs that legislators will need to consider in light of considerable ongoing controversy about handling smoke damage and remediation of toxic substances produced by urban fires and distributed to properties still otherwise intact after the Palisades and Eaton fires of 2025 (see AB 1795, the Smoke Damage Recovery Act, now moving through the California legislature). “Solving” the state’s underinsurance problem seems even more complex – likely requiring both legislation and regulatory action, as well as robust educational efforts to improve (and reinforce) knowledge levels of insurance company staff, insurance intermediaries, and insureds. Then there is the question of whether household incomes of California property owners, particularly in the highest-risk locations around the state, will be able to sustain payments of risk-adjusted, market premiums for wildfire coverage that is sufficient to rebuild structures to pre-fire status.

    The third pathway also includes options that are potentially actionable in the near term (i.e., the next year or two) but that will entail substantial financial commitments from the state. These options include variations on the theme of state financial support for financing wildfire losses – ranging from a new wildfire liability insurance program for utilities to a state-run/state-financed wildfire insurer.

    The report stops short of endorsing any of the pathways, strategies, and options it includes. Now the hard work begins – in an election year – for the legislature and the governor’s office to synthesize the possibilities into one or more legislative/regulatory packages.

    If you have questions about the Senate Bill 254 (2025) Study Report and California’s efforts to become more resilient to natural catastrophes, please contact your regular McDermott Will & Schulte lawyer or the author of this alert.

    Authors

    Thomas M. Dawson

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • SEC staff issues statement on broker-dealer registration for crypto user interfaces

    SEC staff issues statement on broker-dealer registration for crypto user interfaces

    ARTICLE / CLIENT ALERT

    SEC staff issues statement on broker-dealer registration for crypto user interfaces

    April 20, 2026

    Read time: 6 min

    Key takeaways
    Overview

    On April 13, 2026, the US Securities and Exchange Commission (the SEC)’s Division of Trading and Markets (the staff) issued a statement (the statement) outlining when providers of certain crypto asset user interfaces can operate without registering as broker dealers under the Securities Exchange Act of 1934.

    The statement provides some regulatory comfort for self hosted, non custodial interfaces, but clearly draws a line between permissible user interface (UI) and technology layer activity and broker dealer functions, including execution, order routing, discretion, and custody.

    The statement preserves the exemption relied upon by many decentralized finance (DeFi) market participants that function solely in the non-custodial capacity and do not “exercise any control or discretion over, or engage in any decision-making regarding, the market information provided, or securities transactions.” At the same time, the statement expressly excludes providers that route or execute transactions in assets that would be treated as securities, even when those activities are carried out through a self-custody model.

    The statement reflects the views of the staff only and addresses broker-dealer registration issues. Absent action by the SEC, the statement will be withdrawn after five years. Commissioner Hester Peirce, in a separate statement released the same day, also emphasized that the statement provides short-term guidance and the need for a more permanent regulatory solution.

    In depth

    Covered user interfaces

    The statement applies to “covered user interfaces,” which are “interface[s] provided by a website, browser extension, or other software applications … designed to assist users [in preparing] user-initiated crypto asset securities transactions … utilizing [a] self-custodial wallet.” As described by the staff, these interfaces are designed to help users translate transaction terms “into blockchain-legible commands” that can be signed and transmitted through the user’s wallet.

    Covered user interfaces may also display asset prices, estimated transaction costs, or potential execution routes. The staff makes clear that the statement only applies to interfaces that function solely to “prepare code enabling users to interact with blockchain protocols” Interfaces that “execut[e] or settl[e] transactions” fall outside the scope of the statement.

    Clear line between UI technology and broker activity

    A core theme of the statement is the distinction between neutral UI functionality and broker dealer conduct. The staff reiterates that any person “engaged in the business of effecting transactions in securities for the account of others” must register as a broker dealer unless an exemption applies. (See also 15 U.S.C. § 78c(a)(4).) To remain outside that definition and avoid broker-dealer status, the person who creates, offers, or operates covered user interfaces (i.e., covered user interface providers) must not “execut[e] or settl[e] transactions,” “tak[e] or rout[e] orders,” “hold[] [or] access … user funds,” or “provid[e] [investment] advice” or recommendations.”

    The staff makes clear that execution, routing, and custody remain broker dealer functions regardless of whether those activities occur on-chain or through automated systems.

    Sorting and display of execution routes

    The way an interface displays and organizes execution routes is one of the most important aspects of the statement. The staff will not object to interfaces that show multiple execution options or provide filtering and sorting tools only where those tools rely on objective, pre-disclosed, and independently verifiable criteria, such as transaction price or speed.

    The statement clarifies that a covered user interface may not suggest that one route offers the “best price” or is the “most reliable.” The staff signals that this kind of subjective ranking can amount to discretion built into the software itself and can bring the interface closer to broker-dealer activity, even if the interface does not hold assets or execute trades directly. Discretion built into software design itself raises regulatory risk to be classified as a broker-dealer.

    SEC Commissioner Peirce’s insight

    In her separate statement issued on April 13, 2026, SEC Commissioner Hester Peirce welcomed the clarity provided by the statement but cautioned against reading the broker-dealer definition too broadly. Commissioner Peirce noted that “wallets and interfaces do not become ‘brokers’” simply because they enable self-custody, display on-chain data, or transmit transaction instructions to a blockchain.

    Commissioner Peirce warned that requiring registration for tools that merely “touch the financial services industry” could discourage innovation. Commissioner Peirce emphasized that the statement is only a temporary measure because it will be withdrawn after five years unless the SEC takes further action. Commissioner Peirce outlined how a more permanent regulatory solution is needed to address the broker definition in light of evolving market structures.

    Key takeaways and limitations

    The statement draws a clear line between UI tools and broker-dealer activities under the Exchange Act. Trade execution, order routing, settlement, and custody remain broker dealer activities, even when performed through automated or on-chain systems. Interfaces that simply help users prepare transactions and view information using self hosted, non custodial wallets are more likely to fall within the staff’s non objection position.

    The statement makes clear that broker dealer risk is not limited to custody or direct control over trades. How execution options are ranked or described can also create broker-dealer risk. User interface providers can no longer claim an exemption from broker-dealer registration solely because the interface operates on a non-custodial basis.

    The statement offers narrow and temporary guidance, reflecting only the views of the staff and applying to broker-dealer registration issues. It will expire in five years unless the SEC takes further action. Even so, it is likely to shape regulatory expectations in the near term.

    McDermott Will & Schulte’s FinTech and blockchain team can help clients navigate the nuances and practical implications of the SEC’s staff statement and related regulatory developments. The firm’s crypto team is the largest crypto-exclusive team in the industry, with lawyers who dedicate 100% of their time serving the crypto industry and a dedicated sub-team focused on crypto regulatory and licensing matters. McDermott Will & Schulte is one of the few firms ranked Band 1 by Chambers USA in crypto-asset disputes.

    Authors

    Nishi K. Gupta

    Partner

    New York – One Vanderbilt Avenue

    Ethan M. Heller

    Associate

    New York – One Vanderbilt Avenue

    Jordan S. Zaia

    Associate

    New York – One Vanderbilt Avenue

    More insights

  • President Trump imposes Section 232 tariffs on pharmaceuticals: What importers need to know

    President Trump imposes Section 232 tariffs on pharmaceuticals: What importers need to know

    ARTICLE / CLIENT ALERT

    President Trump imposes Section 232 tariffs on pharmaceuticals: What importers need to know

    April 20, 2026

    Read time: 7 min

    Key takeaways
    Overview

    On April 2, 2026, President Trump issued a proclamation imposing tariffs on patented pharmaceutical products and their ingredients under Section 232 of the Trade Expansion Act of 1962. The tariffs, which can reach as high as 100%, were imposed to address the national security threat that the administration believes is posed by US reliance on foreign sources of such merchandise. This alert summarizes the key features of the tariff regime and identifies important exceptions that may benefit importers. The tariffs will take effect on July 31, 2026, for certain large pharmaceutical companies (listed in Annex III to the proclamation) and September 29, 2026, for all others. Generic pharmaceuticals and biosimilars are expressly excluded from the tariffs.

    Importers of covered products should carefully review the proclamation and annexes to determine the new tariff’s effects on their merchandise; such reviews should include evaluating country-of-origin implications. Importers also should consider steps such as onshoring or pricing agreements, which come with lower duty rates. Finally, importers should watch for further guidance from the Department of Commerce and the Department of Health and Human Services (HHS) and prepare for further changes, as the new regime has built-in escalators that will increase rates in several years absent further executive action.

    In depth

    Background

    As part of his administration’s broader protectionist push, President Trump directed the Secretary of Commerce Howard Lutnick to conduct several investigations pursuant to Section 232 of the Trade Expansion Act of 1962. One such investigation was to “determine the effects on national security of imports of pharmaceuticals, pharmaceutical ingredients, and related products.” The investigation found that the United States is heavily reliant on imports despite being a leader in pharmaceutical research and development. The secretary argued that this dependence threatens US access to life-saving medications in the event of global supply chain disruptions. It is this investigation that serves as the basis for the imposition of the new tariffs.

    The new tariffs

    What’s covered: Patented pharmaceutical articles

    The tariffs apply to “patented pharmaceutical articles,” which the annexes to the proclamation define as products that:

    • Are subject to a valid, unexpired US patent.
    • Are listed in the FDA’s Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or Purple Book (Lists of Licensed Biological Products).
    • Include ingredients (APIs and key starting materials) for such articles.

    Tariff rates

    The proclamation establishes a tiered tariff structure based on several factors, including the country of origin and whether the importer has entered into agreements with the US government.

    Category Tariff Rate
    Default rate (patented pharmaceuticals and ingredients) 100%
    Trade deal countries (currently, EU Member States, Japan, South Korea, Switzerland/Liechtenstein) 15%
    United Kingdom 10% (subject to further reduction under the US-UK pharmaceutical agreement)
    Companies with approved onshoring plans 20% (rising to 100% on April 2, 2030)
    Companies with most-favored nation (MFN) pricing and onshoring agreements 0% (through January 20,2029)

    Importantly, if a product is subject to more than one duty rate, the lowest rate applies.

    For most covered products, the Section 232 tariff rates shown above are “all-inclusive,” meaning they include the base MFN rate that would otherwise apply under the Harmonized Tariff Schedule of the United States (HTSUS). In other words, if a product has an existing MFN duty rate that is lower than the applicable Section 232 rate (100%, 15%, or 20%), the sum of the MFN rate and the Section 232 duty equals the rate in the proclamation. If the MFN rate exceeds the Section 232 rate, only the MFN rate applies. This effectively caps the duty at the stated Section 232 rates for most products. Importantly, this “all-inclusive” treatment does not apply to UK-origin products. For those articles, the 10% rate stacks on top of the applicable MFN tariff rate.

    The proclamation authorizes the secretary of Commerce to increase tariff rates on companies that fail to fulfill commitments under onshoring plans or agreements, including the potential to impose tariffs retroactively in cases of fraud or deliberate misrepresentation.

    Tariff exceptions

    US-origin products

    Imports of US-origin pharmaceutical products are not subject to the tariffs. The annexes provide a zero rate for pharmaceutical products with an API packaged in dosage form that is a product of the United States.

    Generic pharmaceuticals

    Generic pharmaceuticals, biosimilars, and their associated ingredients are currently expressly excluded from the tariffs. The secretary of Commerce will reassess this exclusion within one year. A “generic pharmaceutical article” is defined as an FDA-approved pharmaceutical article (and associated ingredients) that is not subject to a valid, unexpired US patent and is off exclusivity. This includes products approved pursuant to any of the following:

    • An abbreviated new drug application (ANDA) under Section 505(j) of the Federal Food, Drug, and Cosmetic Act.
    • A new drug application under Section 505(b)(2) that has been deemed therapeutically equivalent to a listed drug.
    • A biosimilar biologics application under Section 351(k) of the Public Health Services Act.
    • An application for an authorized generic drug or authorized biological product, provided the products are imported by a generic or biosimilar manufacturer.

    Specialty pharmaceuticals

    Certain specialty pharmaceutical products are eligible for a zero rate, provided they are from a jurisdiction that has a trade and security framework agreement with the United States, or they meet an urgent US health need. Eligible specialty products include:

    • Orphan drugs (drugs for which all approved indications are designated as orphan pursuant to the Orphan Drug Act and its implementing regulations).
    • Nuclear medicines.
    • Plasma-derived therapies.
    • Fertility treatments.
    • Cell and gene therapies.
    • Antibody drug conjugates.
    • Medical countermeasures related to chemical, biological, radiological, and nuclear threats.
    • Pharmaceutical products for animal health.
    • Other specialty pharmaceutical products to be identified by the secretary of Commerce.

    The secretary of Commerce will publish Federal Register notices when these exemption determinations are made.

    Other exempted articles (Annex IV)

    Annex IV to the proclamation lists specific HTSUS codes that are subject to a zero-tariff rate. These cover a broad range of pharmaceutical chemicals, vitamins, hormones, antibiotics, and other pharmaceutical preparations. Notably, products listed in Annex IV are also exempt from the temporary import surcharge imposed under Proclamation 11012 on February 20, 2026.

    Effective dates

    The tariffs take effect on July 31, 2026, for those companies listed in Annex III, and September 29, 2026, for all others.

    Key takeaways

    First and foremost, importers of pharmaceuticals should review their product portfolios to determine which of their imports will be subject to the new tariffs, with a particular emphasis on evaluating country-of-origin implications. Products from trade deal countries (EU Member States, Japan, South Korea, Switzerland/Liechtenstein, and the UK) face significantly lower tariff rates than products from other countries. Importers also should review which products will be covered by the various exceptions to the new tariffs (e.g., generics and orphan drugs).

    Additionally, importers should take the following steps:

    • Consider onshoring and pricing agreements. Companies that enter into MFN pricing agreements with HHS and onshoring agreements with Commerce can reduce their tariff rates to zero through January 2029. Companies that sign onshoring agreements only will face a 20% rate.
    • Watch for further guidance. The Departments of Commerce and HHS will publish additional guidance regarding the criteria for onshoring plans and the process for entering into MFN pricing agreements. The secretary of Commerce will also publish Federal Register notices identifying additional specialty products that may qualify for exclusions.
    • Prepare for further changes. The tariff regime includes built-in escalators: the 20% onshoring-plan rate increases to 100% on April 2, 2030, and the zero-rate MFN pricing benefit expires on January 20, 2029. The secretary will also reassess the generic pharmaceutical exclusion within one year.
    Authors

    Kristian A. Werling

    Partner

    Chicago

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    R. Bray McDonnell

    Associate

    Washington, DC

    More insights

  • Virginia further restricts noncompetition agreements

    ARTICLE / CLIENT ALERT

    Virginia further restricts noncompetition agreements

    April 15, 2026

    Read time: 4 min

    Key takeaways
    Overview

    Effective July 1, 2026, noncompetition agreements in Virginia will only be enforceable if an employer provides severance benefits, unless the employee is terminated for cause. This further amends the previous version of the law, which also restricts the use of noncompetes for low-wage employees. The amendment is not retroactive and only applies to agreements entered into, amended, or renewed after July 1, 2026.

    In depth

    Virginia’s law previously only prohibited noncompetes for “low-wage employees,” defined as those earning less than the average weekly wage of the Commonwealth or who are entitled to overtime under the federal Fair Labor Standards Act. As of 2026, the average weekly wage is calculated to be $1,507.01 per week, or $78,364.52 over a full year. The definition of “low-wage employees” also includes interns, students, apprentices, certain trainees employed in trades and occupations, and independent contractors compensated at an hourly rate less than the median hourly wage for Virginia according to the Bureau of Labor Statistics for the US Department of Labor.

    The law defines “covenant not to compete” broadly to include any provision in an employment contract “that restrains, prohibits, or otherwise restricts an individual’s ability” to compete with their former employer following termination. The law also provides that these agreements cannot “restrict an employee from providing a service to a customer or client of the employer if the employee does not initiate contact with or solicit the customer or client.” It does not include agreements related to trade secrets or confidential information.

    Penalties for violations are potentially steep. Courts have the power to grant broad remedies where an employee challenges enforcement, including granting injunctive relief and awarding liquidated damages and reasonable attorneys’ fees. Employers are also required to pay $10,000 fines for each violation of the law.

    In addition to banning noncompetes for low-wage employees, the amended law provides that noncompetes are only enforceable if employers provide “severance benefits or other monetary payment to” terminated employees, unless the employee is discharged for cause. The law does not define “cause.” It also requires that the severance benefits or other monetary payment “be disclosed upon execution” of the noncompetition agreement. The law does not specify what constitutes adequate benefits.

    This follows the Court of Appeals of Virginia’s January 2026 decision in Sentry Force Security, LLC v. Barrera, which held that the prohibition on noncompetes extends to employee nonsolicitation agreements and to restrictions on a former employee’s ability to accept business from a customer when the employee has not initiated contact or solicited that customer.

    Next steps

    Given these new restrictions, Virginia employers should review their employment agreements and adjust accordingly.

    For assistance in drafting and enforcing restrictive covenant agreements – in Virginia or elsewhere – please contact your regular McDermott Will & Schulte lawyer or one of the authors.

    Authors

    Barrick Bollman

    Partner

    Chicago

    Brian Mead

    Partner

    Chicago

    Charles Carr

    Associate

    Chicago

    More insights

  • Alabama sends consumer privacy bill to governor

    ARTICLE / CLIENT ALERT

    Alabama sends consumer privacy bill to governor

    April 14, 2026

    Read time: 7 min

    Key takeaways
    Overview

    On April 8, 2026, Alabama’s legislature passed House Bill 351, the Alabama Personal Data Protection Act (the APDPA), which now goes to Alabama’s governor, Kay Ivey, for signature. If signed, the law will take effect May 1, 2027.

    The APDPA has a very low threshold for applicability compared to other state privacy laws and includes some variation from the standard Virginia and Connecticut models. Companies, including larger nonprofits, should therefore evaluate application of the APDPA and prepare for it to come into effect.

    In depth

    Who does the APDPA apply to?

    The APDPA applies to a controller or processor that conducts business in Alabama or produces products or services that are targeted to Alabama residents and meets either of the following criteria:

    • It controls or processes the personal data of more than 25,000 consumers (excluding information processed solely to complete a payment transaction).
    • It derives more than 25% of gross revenue from the sale of personal data.

    Key to these thresholds is that the APDPA is not limited to for-profit companies. While there is an exemption for smaller for-profit businesses and smaller nonprofits (discussed below), the APDPA will apply to larger nonprofit organizations.

    Who is a consumer?

    The definition of “consumer” in the APDPA aligns with the majority of other state consumer privacy laws.

    A “consumer” is “an individual who is a resident of [Alabama].” However, the term does not include individuals acting in a commercial or employment context.

    What is personal data?

    Similarly, there are not any surprises in the definition of “Personal Data.”

    Personal data in the APDPA is “any information that is linked or reasonably linkable to an identified or identifiable individual.” The term does not include deidentified data or publicly available information.

    What is sensitive data?

    Following the more narrow state consumer privacy law definitions of sensitive data, the APDPA defines “sensitive data” as:

    • Data revealing racial or ethnic origin, religious beliefs, a mental or physical health condition or diagnosis, information about an individual’s sex life, sexual orientation, or citizenship or immigration status;
    • The processing of genetic or biometric data for the purpose of uniquely identifying an individual;
    • Personal data collected from a known child; and
    • Precise geolocation data.

    As in some of the newer state consumer privacy laws, “precise geolocation data” is defined as “information derived from technology, including, but not limited to, global positioning system level latitude and longitude coordinates, which directly identifies the specific location of an individual with precision and accuracy within a radius of 1,750 feet.”

    Who can enforce the APDPA?

    Alabama’s attorney general has exclusive enforcement authority. Prior to initiating an action for a violation, the attorney general must provide a notice of violation to the controller and give the controller 45 days to cure the alleged violation. To cure the violation, the controller must correct the violation and provide the attorney general an “express written statement” that the violation has been corrected and that no such further violations will occur. If the controller fails to do so, the attorney general may bring an action for an injunction and assess a civil penalty of up to $15,000 per violation.

    Who is exempt?

    While many of the usual entity types are exempt from the APDPA, the bill exempts a longer list of entities and data types as compared to other state consumer privacy laws. This is yet another reason that companies should review the APDPA to assess its applicability.

    Perhaps the most notable of these new exemptions are for-profit entities with fewer than 500 employees and nonprofit entities of fewer than 100 employees as long as those entities are not selling personal data.

    There is also an interesting carveout specifically for artificial intelligence models: They are exempt as long as they do not contain and cannot be used to extract personal data.

    At the entity level, some of the standard exemptions in the APDPA include state political subdivisions, financial institutions subject to the Gramm-Leach-Bliley Act, covered entities and business associates under the Health Insurance Portability and Accountability Act (HIPAA), and institutions of higher education, among others.

    At the data level, exemptions include, but are not limited to, protected health information and other information regulated under HIPAA, consumer information protected by the Fair Credit Reporting Act, and the Driver’s Privacy Protection Act.

    What obligations are imposed?

    The APDPA imposes controller obligations that largely mirror what we have seen in other states, with a few wrinkles. The obligations include requirements to:

    • “Limit the collection of personal data to what is adequate, relevant, and reasonably necessary in relation to the purposes for which such data is processed”;
    • “Establish, implement, and maintain reasonable administrative, technical, and physical data security practices”;
    • Prohibit processing personal data in violation of the laws that prohibit unlawful discrimination against consumers and refrain from discriminating against consumers that exercise their rights;
    • “Provide an effective mechanism for a consumer to revoke the consumer’s consent”;
    • Process sensitive data only with consent of the consumer;
    • Provide a clear privacy notice explaining how the company processes information and how consumers can exercise their rights; and
    • Recognize GPC signals as of January 1, 2028, for the online opt-out of targeted advertising.

    What is not required by the APDPA are any forms of data impact assessments.

    What consumer rights are created by the APDPA?

    Like other state privacy laws, the APDPA gives consumers certain rights, with respect to their personal data, to:

    • Confirm whether a controller is processing their personal data and accessing any such data under the control of the controller (unless doing so would reveal a trade secret);
    • Correct inaccuracies in their personal data;
    • Direct the controller to delete their personal data;
    • Obtain a portable copy of their personal data (unless doing so would reveal a trade secret); and
    • Opt out of their personal data being processed for targeted advertising, sale, or profiling in furtherance of solely automated significant decisions.

    Significantly, there is no right to appeal a denial of a consumer-rights request under the APDPA.

    Response to consumer requests

    Controllers must respond to an authenticated consumer request within 45 days after receipt, with one additional 45-day extension available upon notice to the consumer when reasonably necessary due to the complexity and number of requests. If a controller declines to act, it must explain the basis for the denial within the initial 45-day period. Responses must be provided free of charge up to once annually per consumer, and controllers may respond to manifestly unfounded, excessive, technically infeasible, or repetitive requests by charging the consumer a reasonable fee or denying the request. The bill also provides a specific compliance pathway for deletion requests when the controller obtained the personal data from a source other than the consumer.

    When does the APDPA take effect?

    If signed into law, the APDPA will go into effect May 1, 2027.

    * * *

    The state privacy law landscape continues to become more complex as each new omnibus law is introduced. If the APDPA is signed into law, organizations should review applicability, consumer-rights workflows, notices, controller-processor contracts, sensitive-data consent flows, and assessment practices to determine whether targeted Alabama updates are warranted. If you have questions or need assistance with readiness work for new state consumer privacy laws, please contact your regular McDermott lawyer.

    Authors

    David Sorenson

    Associate

    Los Angeles

    David P. Saunders

    Partner

    Chicago

    More insights

  • Getting Form 483 responses right: FDA’s March 2026 draft guidance explained

    ARTICLE / CLIENT ALERT

    Getting Form 483 responses right: FDA’s March 2026 draft guidance explained

    April 14, 2026

    Read time: 7 min

    Key takeaways
    Overview

    In its March 2026 draft guidance, the US Food and Drug Administration (FDA) outlined its current thinking on how drug and certain product manufacturers should approach Form 483 responses to inspectional observations issued at the conclusion of a current good manufacturing practice (CGMP) inspection. The FDA emphasized that Form 483s reflect inspectional observations rather than final compliance determinations, but noted that a manufacturer’s response may serve as a key input into the agency’s assessment of whether further regulatory action is warranted. The draft guidance provides recommendations regarding the content, format, and timing of responses to Form 483 when manufacturers choose to submit them.

    The FDA will accept comments from industry and the public on the draft guidance through May 8, 2026.

    In depth

    Background

    FDA Form 483s are issued when FDA investigators observe conditions or practices that, in their judgment, may constitute violations of the Federal Food, Drug, and Cosmetic Act. Form 483 provides notice to the inspected establishment of significant inspectional observations identified during the inspection, but it does not represent the FDA’s final compliance determination or an enforcement decision.

    Consistent with long-standing CGMP requirements, drug manufacturers remain responsible for investigating and correcting deficiencies and ensuring ongoing compliance, regardless of whether they submit a written response to a Form 483 or receive feedback from the FDA. The draft guidance is intended to promote clear and effective communication between the FDA and industry and to clarify the agency’s current thinking on best practices for responding to inspectional observations, including how manufacturers should assess risk, conduct investigations, and implement and evaluate corrective and preventive actions.

    The guidance applies to domestic and foreign manufacturers of human and animal drugs regulated by the FDA’s Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), and Center for Veterinary Medicine (CVM), as well as certain combination product manufacturers where CDER or CBER is the lead center. While the guidance is focused on these product areas, many of the principles discussed may also be useful when responding to Form 483 observations for other product areas or when preparing responses to FDA warning letters.

    Why it matters

    Recent FDA enforcement actions reflect increasing scrutiny of both inspectional findings and manufacturers’ post inspection responses. For example, FDA warning letters often reference Form 483 responses and consider the adequacy of those responses when evaluating whether inspectional observations have been addressed, including whether manufacturers have identified root causes, provided supporting documentation, and implemented corrective actions. Where the FDA has identified repeat or unresolved observations, the agency has characterized such issues as indicative of systemic compliance failures, which could increase the likelihood of enforcement escalation.

    Submitting a response to Form 483

    The draft guidance reiterates the FDA’s recommendation that establishments submit a single comprehensive written response within 15 business days of the Form 483 issuance. The FDA explains that responses received within this timeframe are generally reviewed in detail before the agency determines whether to pursue subsequent regulatory action, whereas responses submitted after 15 business days may not delay enforcement action.

    The FDA further recommends that Form 483 responses be accurate, clear, concise, and well organized and demonstrate that the establishment is addressing, or actively working to address, both the specific observations and the underlying issues that led to them. The guidance identifies core elements that should be included in a written response, such as:

    • Identification of the inspected establishment (including facility information and FDA establishment identifier)
    • A copy of the Form 483
    • Identification of the response preparer and signatory
    • An executive summary describing remediation activities and associated corrective actions.

    Investigations and risk assessment

    The draft guidance places significant emphasis on robust, scientifically justified investigations. The FDA recommends that establishments develop written investigation plans that clearly define scope, methodology, and a risk based rationale, including justification for any operations, products, or facilities excluded from the investigation.

    The FDA further advises that investigations extend beyond the specific observation cited to assess whether identified deficiencies may affect other drugs or batches, manufacturing processes or systems, additional facilities, or contract manufacturing or testing organizations. In conducting these assessments, manufacturers are encouraged to evaluate trends, prior inspection findings, and internal audit results to determine whether observations reflect broader or systemic issues. The agency cautions that addressing only the most apparent or immediate cause of an observation may be insufficient and may not prevent recurrence.

    The guidance also underscores the importance of patient  and product focused risk assessments, including evaluation of inventory and distributed drugs still within expiry and any potential impact on safety, identity, strength, quality, or purity.

    CAPA development and effectiveness

    The FDA encourages manufacturers to begin developing corrective and preventive action (CAPA) plans during or immediately following the inspection, with plans further refined as investigations progress. CAPAs should be commensurate with the level of risk identified and structured to address root causes, rather than symptoms, of observed deficiencies.

    According to the guidance, effective CAPA plans should include:

    • Defined timelines and measurable milestones
    • Interim control measures, where remediation cannot be completed promptly
    • Clear deliverables
    • Communication plans for providing follow up updates to the FDA.

    CAPAs should be implemented across all affected areas, and manufacturers are expected to verify that CAPAs are effective and do not result in unintended consequences. The FDA emphasizes that evaluation of CAPA effectiveness is a critical component of compliance, noting that routine testing alone may be insufficient. Where effectiveness checks are inadequate, manufacturers may need to revisit root cause analyses and CAPA strategies. FDA notes that it may verify CAPA implementation and effectiveness during subsequent inspections.

    Management responsibility and oversight

    The draft guidance highlights management’s central role in responding to Form 483 observations. The FDA expects management to review inspectional observations at both the facility and corporate levels, ensure appropriate allocation of resources, and support multidisciplinary investigation teams. Although manufacturers may engage consultants, the FDA emphasizes that ultimate responsibility for CGMP compliance remains with the establishment.

    The FDA recommends that management consider why deficiencies were not previously identified or addressed by the quality system and assess whether improvements to quality culture, governance, or oversight mechanisms are necessary to prevent future issues.

    Resolving scientific or technical disagreements

    Where scientific or technical disagreements arise, the FDA encourages establishments to seek clarification during the inspection and to document unresolved issues in the written response. Responses should clearly describe the contested facts and provide supporting scientific data, as well as references to applicable statutes, regulations, or FDA guidance.

    The draft guidance also identifies the FDA’s formal dispute resolution processes and the Office of the Ombudsman as potential avenues for further escalation when disagreements cannot be resolved through the inspection or response process.

    Next steps

    Drug and product manufacturers may wish to review their post‑inspection procedures and internal escalation frameworks in light of the FDA’s draft guidance, including timelines for response preparation, investigation planning, and executive management review. Establishments may also consider whether their current approaches to root cause analysis, CAPA development, and effectiveness evaluation align with the FDA’s articulated expectations. Companies should evaluate whether to submit comments on the draft guidance to the FDA by the May 8, 2026, deadline.

    The McDermott difference

    McDermott Will & Schulte will continue to monitor the FDA’s finalization and implementation of this guidance and its broader enforcement posture with respect to CGMP inspections. If you have questions about how this draft guidance may affect your inspection response strategy, please contact a member of our Food, Drug & Medical Device Group.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Paul S. Gadiock

    Partner

    San Francisco

    Tyler Barton

    Associate

    New York – One Vanderbilt Avenue

    More insights

  • Tax-Free Bonus 2.0 – What Employers Need to Know About the “Relief Bonus”

    Tax-Free Bonus 2.0 – What Employers Need to Know About the “Relief Bonus”

    ARTICLE / CLIENT ALERT

    Tax-Free Bonus 2.0 – What Employers Need to Know About the “Relief Bonus”

    April 14, 2026

    Read time: 2 min

    Key takeaways
    Overview

    On April 13, 2026, the coalition committee agreed on the introduction of a “relief bonus” of up to €1,000. Details on its specific design are not yet available. However, similar to the inflation compensation bonus during the COVID-19 pandemic, employers are expected to have the option to grant employees a tax- and social security-privileged special payment.

    Find out what employers need to consider from an employment law perspective in our HR News blog post by Dr. Thomas Gennert and Lisa Scheipers. Visit the blog and/or register now for regular HR News updates (in German).

    In depth
    Authors

    Dr. Thomas Gennert

    Partner

    Düsseldorf

    More insights

  • Incoming from Delaware: Unclaimed Property VDA Program invitation notices have been sent out

    Incoming from Delaware: Unclaimed Property VDA Program invitation notices have been sent out

    ARTICLE

    Incoming from Delaware: Unclaimed Property VDA Program invitation notices have been sent out

    Apr 13, 2026

    Read time: 4 min

    Key takeaways
    Overview

    The Delaware Office of the Secretary of State (SOS) confirmed that on April 10, 2026, invitation notices were sent to businesses (holders) identified as potentially out of compliance with Delaware’s unclaimed property law. The notices encourage holders to enroll in the SOS Unclaimed Property Voluntary Disclosure Agreement (VDA) Program within 90 days of receipt of the notice and cautions that failure to do so will result in the holder being referred to a peer state agency (the Department of Finance) for examination – the day-to-day of which is conducted by one of Delaware’s third-party unclaimed property audit firms. As a result, these seemingly routine initial regulatory compliance notices should not be ignored, and it is critical that companies be on the lookout for these notices and respond in a timely manner.

    VDA Program invitations are typically sent to the holder’s chief financial officer (CFO) via certified mail. Given the history of these notices being lost, delayed in the mailroom, or forwarded to the wrong department, it may be prudent for those responsible for unclaimed property compliance to check with their CFO in the coming weeks on whether a letter from the SOS was received since the 90-day clock is imminent. Recipients of these invitations range from middle-market companies to Fortune 100 companies, both privately and publicly held, across a wide range of industries, including oil and gas, retail, banking, utilities, technology, media, healthcare, manufacturing, pharmaceutical, and consumer products. However, there has recently been a noticeable increase in invitations sent to companies that maintain a long filing history but may have been involved in recent merger or acquisition activity. Additionally, companies that have formed within the last 10 years but have experienced rapid growth over the last few years are at higher risk of receiving invitations. This group includes startups that have recently gone public; cloud and artificial intelligence companies; and companies with online and transient customer bases, such as payment processers and online marketplaces. Delaware incorporated entities with a large presence of foreign owned (or unknown) property on their books and records are always at risk of an unclaimed property regulatory compliance review by Delaware.

    The lookback period for both the unclaimed property audits and the VDA Program is 10 report years, plus the five-year dormancy period for most property types, equating to a 15-year lookback period. Often, complete and researchable books and records are not available for the full lookback period and the VDA Program regulations require estimation for the older periods.

    Enrolling in the VDA Program offers several benefits, including, but not limited to, a waiver of Delaware’s statutory penalties, a significant reduction in interest paid on any findings, control over the process, a 90-day aging criteria for voided disbursement checks that limits the workload (compared to the traditional 30-day period), and not being referred to the Department of Finance – which has the potential to turn into a multistate audit.

    Holders that receive an invitation to the VDA Program from the SOS in the coming weeks are encouraged to promptly contact the authors of this blog post regarding company-specific implications, options, and next steps. McDermott Will & Schulte is a holder advocate that regularly guides clients through the VDA Program and key strategic and legal decisions that come up throughout the multiyear VDA process.

    Authors

    Stephen P. Kranz

    Partner

    Washington, DC

    Eric D. Carstens

    Partner

    Washington, DC

    More insights
    Endnotes

  • SEC enforcement action acts as valuation processes reminder for credit funds

    SEC enforcement action acts as valuation processes reminder for credit funds

    ARTICLE / CLIENT ALERT

    SEC enforcement action acts as valuation processes reminder for credit funds

    April 8, 2026

    Read time: 4 min

    Key takeaways
    Overview

    The US Securities and Exchange Commission (SEC) recently announced a settled administrative enforcement action against a formerly registered investment adviser (the Adviser) in connection with the Adviser’s valuation practices for affiliated principal transactions involving private credit funds it advised. Although the conduct dates back to March 2020 and the start of COVID-19, the action highlights the SEC’s focus on credit markets and valuation processes and disclosures, particularly during periods of market stress.

    In depth

    Overview of the enforcement action

    According to the SEC’s order, the Adviser employed a “season and sell” strategy under which it originated senior loans and, after typically holding them for 30 to 60 days, sold portions of those loans to private funds it advised in principal transactions. Fund agreements and investor disclosures represented that such transactions would be priced at fair value as reasonably determined by the Adviser.

    The SEC found that during the onset of COVID 19, the Adviser continued to price loan transfers using a mechanical formula (par value less unamortized loan fees) without reassessing whether market volatility and liquidity conditions affected fair value. The SEC concluded that this failure to reassess valuation rendered the Adviser’s practices inconsistent with its disclosures.

    The SEC did not allege intentional misconduct. Instead, the action was premised on negligence based anti-fraud provisions, which is similar to another action we recently covered. This also reflects the SEC’s view that valuation methodologies should be actively reevaluated when market conditions materially change. Notably, the SEC indicated that all but one of the loans fully performed or were repaid.

    Without admitting or denying the findings, the Adviser consented to a cease and desist order, censure, and $900,000 civil monetary penalty for violations of Sections 206(2) and 206(4) of the Investment Advisers Act of 1940 and Rule 206(4) 8 thereunder. The SEC did not seek disgorgement because in response to an SEC staff examination deficiency letter concerning the conduct, the Adviser voluntarily reimbursed the funds ($5,010,854.90, plus $203,819.69 in interest) as compensation.

    Key takeaways

    • Private credit managers should review their valuation policies and disclosures.
      • Valuation is a process, not a formula. The SEC emphasized that reliance on static pricing methodologies may be insufficient when market conditions materially change, particularly in affiliated transactions where conflicts are inherent.
      • Disclosures set the standard. Where governing documents and disclosures promise fair value determinations, advisers should consider whether contemporaneous practices reflect that commitment in substance, not merely in form. Advisers also should consider whether disclosures are aligned with practice not only in ordinary markets, but under stressed conditions as well.
      • Market stress heightens expectations. Periods of volatility, even if relatively brief, do not relax fair value obligations; they intensify them. Managers should expect the SEC to scrutinize whether valuation methodologies were reassessed in real time as market conditions evolved. An aggressive SEC may be willing to second guess an adviser’s valuation.
      • Third party consent is not a safe harbor. While the Adviser used third party review agents for principal transaction consent, the SEC’s case focused on valuation integrity rather than consent mechanics, underscoring that procedural compliance alone may be insufficient.
    • Principal trades will likely be a focus. Principal transactions between advisers and affiliated funds remain a core enforcement priority. Valuation is often the lens through which the SEC evaluates whether conflicts were adequately managed.
    • Negligence based cases remain a priority. This recent action continues a trend of SEC enforcement grounded in fiduciary duty and disclosure failures rather than scienter based fraud.
    • Exams as a pipeline for enforcement. Examinations remain a key source of enforcement activity, particularly where disclosures and practices diverge.
    • Remediation does not foreclose enforcement. The SEC’s willingness to seek an enforcement action and impose penalties despite post exam remediation reinforces that remedial measures, while important, may not eliminate enforcement risk if past conduct diverged from disclosures.
    Authors

    Allison Scher Bernbach

    Partner

    New York – One Vanderbilt Avenue

    Marc E. Elovitz

    Partner

    New York – 919 Third Avenue

    Paul M.G. Helms

    Partner

    Chicago, Washington, DC

    Kelly Koscuiszka

    Partner

    New York – 919 Third Avenue

    John P. Nowak

    Partner

    New York – 919 Third Avenue

    More insights